These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22486062)

  • 21. [Importance of the "adequate blood phosphorus" concept as a risk factor for hyperphosphatemia].
    Douthat WG; Alles A; Marinovich S; Tirado S; Peñalba A; Prudkin S
    Nefrologia; 2003; 23 Suppl 2():95-9. PubMed ID: 12778863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteodystrophy in patients with chronic renal failure.
    Fearing MO
    Nurs Clin North Am; 1975 Sep; 10(3):461-8. PubMed ID: 1041628
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.
    Klaus G; Watson A; Edefonti A; Fischbach M; Rönnholm K; Schaefer F; Simkova E; Stefanidis CJ; Strazdins V; Vande Walle J; Schröder C; Zurowska A; Ekim M;
    Pediatr Nephrol; 2006 Feb; 21(2):151-9. PubMed ID: 16247644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Renal osteodystrophy during chronic dialysis and transplantation].
    Fournier A; Bordier P; Weil B; Safar M; Idatte JM
    Presse Med (1893); 1971 Oct; 79(45):2007-8. PubMed ID: 4940843
    [No Abstract]   [Full Text] [Related]  

  • 25. Osteodystrophy developing spontaneously in the course of chronic renal failure.
    Stanbury SW; Lumb GA; Mawer EB
    Arch Intern Med; 1969 Sep; 124(3):274-81. PubMed ID: 5806041
    [No Abstract]   [Full Text] [Related]  

  • 26. [Vitamin D treatment--which analogs and when?].
    Martin PY; Trombetti A; Stoermann C
    Ther Umsch; 2007 May; 64(5):237-41. PubMed ID: 17685080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical management of renal hyperparathyroidism. Pulse treatment with vitamin D metabolites or not?
    Reichel H
    Nephrol Dial Transplant; 1994; 9(10):1368-70. PubMed ID: 7816246
    [No Abstract]   [Full Text] [Related]  

  • 28. Soft bones and hard arteries-can we reverse the trend in CKD?
    Tomlinson J; Cunningham J
    J Ren Care; 2009 Mar; 35 Suppl 1():28-33. PubMed ID: 19222728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can renal bone disease be prevented?
    Shaldon S
    Proc Eur Dial Transplant Assoc; 1973; 10(0):91-123. PubMed ID: 4808119
    [No Abstract]   [Full Text] [Related]  

  • 30. Vitamin d and stage 5 chronic kidney disease: a new paradigm?
    Heaf JG; Joffe P; Marckmann P
    Semin Dial; 2012; 25(1):50-8. PubMed ID: 21967444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventing bone disease requires diligent management in patients with renal failure.
    Kolb FO
    West J Med; 1994 May; 160(5):475-7. PubMed ID: 8048242
    [No Abstract]   [Full Text] [Related]  

  • 32. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease.
    Mathew S; Davies M; Lund R; Saab G; Hruska KA
    Eur J Clin Invest; 2006 Aug; 36 Suppl 2():43-50. PubMed ID: 16884397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenesis of osteomalacia in chronic renal failure and its relationship to vitamin D.
    Kanis JA; Hamdy NA; Cundy T
    Ann Med Interne (Paris); 1986; 137(3):193-9. PubMed ID: 3532899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone disease in renal failure. Introduction.
    Malluche HH
    Miner Electrolyte Metab; 1991; 17(4):209-10. PubMed ID: 1813782
    [No Abstract]   [Full Text] [Related]  

  • 35. [Vitamin D metabolism and chronic kidney insufficiency].
    Schaefer K; von Herrath D; Kraft D
    Dtsch Med Wochenschr; 1973 Jul; 98(27):1338-44. PubMed ID: 4351844
    [No Abstract]   [Full Text] [Related]  

  • 36. Update on the new Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for mineral and bone disorders (MBD)--a focus on medications.
    Raymond CB; Wazny LD; Sood AR
    CANNT J; 2010; 20(1):42-6; quiz 47-8. PubMed ID: 20426360
    [No Abstract]   [Full Text] [Related]  

  • 37. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.
    Neves KR; Graciolli FG; dos Reis LM; Pasqualucci CA; Moysés RM; Jorgetti V
    Kidney Int; 2004 Dec; 66(6):2237-44. PubMed ID: 15569312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapeutic agents and strategies for the management of chronic kidney disease mineral and bone disorder.
    Connor A
    Postgrad Med J; 2009 May; 85(1003):274-9. PubMed ID: 19520880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bone disease in patients with chronic renal failure and during long-term hemodialysis].
    Flury W
    Ther Umsch; 1972 Sep; 29(9):554-9. PubMed ID: 4628712
    [No Abstract]   [Full Text] [Related]  

  • 40. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.